You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
25 March 2019
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies to Include Marketed Anti-Tumor Antibodies (news with additional features)
30 July 2018
Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate (news with additional features)
18 July 2018
DCprime and Glycotope announce licensing agreement and collaboration (news with additional features)
22 December 2017
Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies (news with additional features)
21 September 2017
Glycotope lizensiert GlycoExpress Zelllinie an Airway Therapeutics
29 April 2016
Glycotope GmbH: Glycotope ernennt Dr. Alfredo Zurlo zum Chief Medical Officer
7 January 2016
Glycotope GmbH: Glycotope names Paul G Higham as new Chief Executive Officer
8 October 2015
Glycotope GmbH and Octapharma AG: Glycotope and Octapharma enter exclusive worldwide license agreement on human blood coagulation factors
3 August 2015
Glycotope GmbH: Glycotope’s GlycoExpress(TM) glyco-optimization platform reaches clinically validated superior quality and unmet production yields of ADCC-improved antibodies
3 July 2015
Glycotope Biotechnology and Cantargia sign production agreement for lead product candidate CAN04
2 April 2014
Glycotope GmbH: Glycotope medicates first patients in Phase IIb study for novel glycooptimized anti-EGFR antibody CetuGEX(TM) to treat squamous cell carcinomas of the head and neck (SCCHN)
20 March 2014
Glycotope GmbH: Glycotope names Henner Kollenberg as Managing Director and Chief Financial Officer
11 March 2014
Glycotope secures one of the largest financing rounds in the European biotech sector
